Purinergic Signaling and the Postmenopausal Heart
Recruiting · NCT06015776 · Observational (researchers observe without assigning treatment) · Lead sponsor: Beth Israel Deaconess Medical Center
View the official record on ClinicalTrials.gov →Interventions studied
Gender
What this trial is about
There is an increased risk of diastolic heart failure in post menopausal women. Estrogen plays a positive role in regulating molecular pathways in heart remodeling. Such pathways may work through purinergic signaling and its downstream effects on the heart's mitochondrial metabolism and angiogenic response to stress. Loss of estrogen functionality in post menopausal women may account for the increased risk of diastolic heart failure. The investigators will explore said pathways using cardiac tissue obtained from patients undergoing cardiac surgery.
Who can take part
Age range
30 Years to 88 Years
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients undergoing cardiac surgery under cardiopulmonary bypass.
Exclusion criteria
- Refusal to participate
- Emergency surgery
- Pre-existing heart block
- Preexisting atrial fibrillation
- Redo surgery
- Estrogen or hormone replacement therapy
- History of chronic heart failure
- History of major kidney disease
Where it is running
1 location listed across 1 US state.
- Beth Israel Deaconess Medical Center - Boston, Massachusetts, United States